CR Double-Crane

CR Double-Crane Pharmaceuticals is a leading integrated pharmaceutical company in China and a core subsidiary of the China Resources Pharmaceutical Group. Founded in 1939, the company has evolved from a military pharmacy into a large-scale manufacturer specializing in chronic disease management, intravenous infusions, and specialist therapies. Its extensive portfolio includes over 2,000 drug approvals, with market leadership in cardiovascular, endocrine, and pediatric treatments. In recent years, CR Double-Crane has strategically pivoted toward innovation, building a pipeline of over 15 innovative assets in oncology, rare diseases, and regenerative medicine through internal R&D and global partnerships. The company operates more than 20 production bases across China and is listed on the Shanghai Stock Exchange (SSE: 600062).